JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 114 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.78 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $101,000 | -19.2% | 14,942 | +0.2% | 0.00% | – |
| Q4 2021 | $125,000 | +16.8% | 14,918 | +3.8% | 0.00% | – |
| Q3 2021 | $107,000 | +35.4% | 14,372 | +24.1% | 0.00% | – |
| Q2 2021 | $79,000 | -34.7% | 11,579 | -1.8% | 0.00% | – |
| Q1 2021 | $121,000 | +40.7% | 11,787 | -3.9% | 0.00% | – |
| Q4 2020 | $86,000 | -20.4% | 12,260 | -7.6% | 0.00% | – |
| Q3 2020 | $108,000 | -51.8% | 13,274 | -59.1% | 0.00% | – |
| Q2 2020 | $224,000 | +176.5% | 32,475 | +91.3% | 0.00% | – |
| Q1 2020 | $81,000 | -50.0% | 16,978 | -8.7% | 0.00% | – |
| Q4 2019 | $162,000 | +134.8% | 18,604 | -10.4% | 0.00% | – |
| Q3 2019 | $69,000 | -25.8% | 20,762 | +10.2% | 0.00% | – |
| Q2 2019 | $93,000 | -29.5% | 18,847 | -11.4% | 0.00% | – |
| Q1 2019 | $132,000 | +230.0% | 21,264 | +80.6% | 0.00% | – |
| Q4 2018 | $40,000 | -88.7% | 11,776 | -74.5% | 0.00% | – |
| Q2 2018 | $354,000 | – | 46,230 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 572,829 | $1,340,000 | 100.00% |
| TRV GP III, LLC | 1,148,780 | $2,688,000 | 1.17% |
| COWEN AND COMPANY, LLC | 3,647,430 | $8,535,000 | 0.82% |
| Octagon Capital Advisors LP | 1,400,000 | $3,276,000 | 0.56% |
| Deep Track Capital, LP | 4,259,653 | $9,968,000 | 0.46% |
| PFM Health Sciences, LP | 4,094,488 | $9,581,000 | 0.35% |
| RTW INVESTMENTS, LP | 5,106,341 | $11,949,000 | 0.28% |
| Omega Fund Management, LLC | 275,513 | $645,000 | 0.24% |
| Monarch Partners Asset Management LLC | 228,370 | $534,000 | 0.16% |
| Orbimed Advisors | 2,928,900 | $6,854,000 | 0.13% |